20 Jul NKILT Therapeutics
Raphael Ognar, President and CEO, Co-founder
Oct. 10 | 11:15am | Rentschler ATMP Ballroom
NKILT Therapeutics is a new cell therapy biotech developing a novel approach of engineering Natural Killer (NK) cells, and other immune cells, to directly target leukemias and solid tumors. In vitro PoC is confirmed with T cells and NK cells. Our platform is a novel Chimeric ILT-Receptor (CIR), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial armored CIR-NK cells will be able to exquisitely target and directly kill cancer cells but will also activate innate immunity and directly target the tumor’s defense mechanisms. Starting with AML as a pre-clinical/clinical proof of concept, we will rapidly expand to our core focus in solid tumors with priority given to Colorectal Cancer (CRC), Breast and Ovarian cancers and more HLA-G+ tumors. Currently raising our $5M seed round, we hope to name our lead assets and engage with FDA early 2024.